ReviewBioMed research international2014
Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Article
- Bisphenol-A in Drinking Water Accelerates Mammary Cancerogenesis and Favors an Immunosuppressive Tumor Microenvironment in BALB-International journal of molecular sciences · 2024Article
- Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response.Frontiers in immunology · 2024Review
- Phenotypic Analysis of Circulating Myeloid Derived Suppressor Cells and Their Subpopulations in Egyptian Females with Breast Cancer: A Single-Centre Case-Control Study.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.International journal of molecular sciences · 2023Review
- Are Cancer Stem Cells a Suitable Target for Breast Cancer Immunotherapy?Frontiers in oncology · 2022Article
- Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy.Oncoimmunology · 2022Article
- The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.Frontiers in oncology · 2021Review
- Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota.International journal of molecular sciences · 2020Review
- Improvement in the Anti-Tumor Efficacy of Doxorubicin Nanosponges in In Vitro and in Mice Bearing Breast Tumor Models.Cancers · 2020Article
- Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter.Cancer immunology, immunotherapy : CII · 2019Review
- Multiplex three-dimensional optical mapping of tumor immune microenvironment.Scientific reports · 2017Article
- Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Vaccines · 2017Review
- Clinical applications of mouse models for breast cancer engaging HER2/neu.Integrative cancer science and therapeutics · 2016Article
- Vasculature Disruption Enhances Bacterial Targeting of Autochthonous Tumors.Journal of Cancer · 2015Article
- A versatile mathematical work-flow to explore how Cancer Stem Cell fate influences tumor progression.BMC systems biology · 2015Article
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tyrosine kinase human epidermal growth factor receptor 2 (HER2) gene is amplified in approximately 20% of human breast cancers and is associated with an aggressive clinical course and the early development of metastasis. Its crucial role in tumor growth and progression makes HER2 a prototypic oncoantigen, the targeting of which may be critical for the development of effective anticancer therapies. The setup of anti-HER2 targeting strategies has revolutionized the clinical outcome of HER2(+) breast cancer. However, their initial success has been overshadowed by the onset of pharmacological resistance that renders them ineffective. Since the tumor microenvironment (TME) plays a crucial role in drug resistance, the design of more effective anticancer therapies should depend on the targeting of both cancer cells and their TME as a whole. In this review, starting from the successful know-how obtained with a HER2(+) mouse model of mammary carcinogenesis, the BALB-neuT mice, we discuss the role of TME in mammary tumor development. Indeed, a deeper knowledge of antigens critical for cancer outbreak and progression and of the mechanisms that regulate the interplay between cancer and stromal cell populations could advise promising ways for the development of the best anticancer strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.